top of page




The Vaccine Technology Centre (VTC) is the vaccine research centre of Zydus Group. VTC has two state-of-the-art R & D Centers, ETNA BIOTECH located in Catania-Italy and the other in Ahmedabad-India.

ETNA BIOTECH is a company whose key competencies lie in researching and developing vaccines and immunotherapeutics for infectious diseases and other chronic illnesses.


Start up of the former Swiss Serum and Vaccine Institute, later Berna Biotech, ETNA BIOTECH is now company of Zydus Lifesciences, a global healthcare provider and one of the top four pharma companies in India.



> 15 February 2020 - Zydus group launches a fast tracked programme to develop vaccine for the novel coronavirus, 2019-nCoV (COVID-19) - PRESS RELEASE

> 12 December 2018 - Etna Biotech is partner of the bi-rex Competence Center, the first ever public-private consortium in Italy by the Industry 4.0 Plan

> 19-20 March 2018 - Kick-off meeting STriTuVaD (In Silico Trial for Tuberculosis Vaccine Development) funded by European Commission under H2020  []

> 25-29 Sept. 2017 - Summer School 2017 MuLeVaClin in Porto
​> 21-25 Sept. 2015 - Summer School 2015 MuLeVaClin in Madrid
​> 15-19 Sept. 2014 - Summer School 2014 MuLeVaClin in Catania

> 20 Nov. 2013 - European Commission supports EDUFLUVAC project to develop an innovative vaccine against influenza. 
> 18 Nov. 2013 - European Commission funds consortium to develop a Multivalent Vaccine for Human Visceral Leishmaniasis - MuLeVaClin. 




Etna Biotech was funded in 2001 and it is a vaccine research centre of the Zydus group. Zydus is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. Zydus Lifesciences provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products.



Built up on its track record in industrial research, development and production of vaccines Etna Biotech is fully integrated in the Zydus’ Vaccine Technology Center with whom share the same ambition to develop new safe, efficacious and affordable vaccines able to respond the high unmet medical need.



To maximize the potential for Etna Biotech’s technologies and to enhance the prospects of its R&D pipeline, the company has established a strong network of partnerships. 

Such collaborations enable Etna Biotech to explore a wide range of innovative approaches.

bottom of page